热门资讯> 正文
Oragenics宣布与Receptor.AI合作
2025-10-07 20:41
- Oragenics (NYSE:OGEN) on Tuesday said that it has collaboreted with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the development of its neurological drug pipeline.
- The collaboration aims to expand Oragenics’ pharmaceutical pipeline by using advanced AI to identify optimal receptor binding profiles for newly acquired compounds.
- This will support the company's research into treatments for neurological and psychiatric conditions, including Alzheimer’s, Parkinson’s, PTSD, and anxiety disorders.
- OGEN +2.30% premarket to $1.33.
- Source: Press Release
More on Oragenics
- Seeking Alpha’s Quant Rating on Oragenics
- Historical earnings data for Oragenics
- Financial information for Oragenics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
